Antibiotic Therapy for Difficult‐to‐Treat Infections in Lung Transplant Recipients: A Practical Approach

Abstract

Lung transplant recipients are at higher risk to develop infectious diseases due to multidrug resistant pathogens, which often chronically colonize the respiratory tract before transplantation. The emergence of these difficult‐to‐treat infections is a therapeutic challenge, and it may represent a contraindication to lung transplantation. New antibiotic options are currently available, but data on their efficacy and safety in the transplant population are limited, and clinical evidence for choosing the most appropriate antibiotic therapy is often lacking. In this review, we provide a summary of the best evidence available in terms of choice of antibiotic and duration of therapy for MDR/XDR P. aeruginosa, Burkholderia cepacia complex, Mycobacterium abscessus complex and Nocardia spp infections in lung transplant candidates and recipients.